Report Detail

Request for Sample of this report

Pharma & Healthcare Global Peptide Cancer Vaccine Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024

  • RnM2938859
    • |
  • 13 February, 2019
    • |
  • Global
    • |
  • 119 Pages
    • |
  • GIR (Global Info Research)
    • |
  • Pharma & Healthcare

Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.

Scope of the Report:
Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.
With the ever increasing new cancer cases across the globe and the conventional treatment methods unable to cope up with the challenges posed by the tumor and their immune response evading techniques, cancer immunotherapy brings a ray of hope. Cancer immunotherapy allows the host's immune cells to get sensitized with the tumor-associated antigens which in turn elicits B cell and T cell mediated immune response to target and eliminate tumor cells. This is the underlying principle of cancer immunotherapy.
Peptide Cancer Vaccine can be used for Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer and Others cancers. The most proportion research of Peptide Cancer Vaccine is about Melanoma, and the proportion in 2025 is about 40%.
The worldwide market for Peptide Cancer Vaccine is expected to grow at a CAGR of roughly 23.1% over the next five years, will reach 780 million US$ in 2024, from 280 million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Peptide Cancer Vaccine in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Market Segment by Manufacturers, this report covers
TapImmune
BrightPath Biotherapeutics
Ultimovacs
Sellas
Boston Biomedical
Imugene
VAXON Biotech
Generex Biotechnology
ISA Pharmaceuticals
OncoTherapy Science
Immatics

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
Type I
Type II

Market Segment by Applications, can be divided into
Breast Cancer
Lung Cancer
Melanoma
Prostate Cancer
Others

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Peptide Cancer Vaccine product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Peptide Cancer Vaccine, with price, sales, revenue and global market share of Peptide Cancer Vaccine in 2017 and 2018.
Chapter 3, the Peptide Cancer Vaccine competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Peptide Cancer Vaccine breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Peptide Cancer Vaccine market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Peptide Cancer Vaccine sales channel, distributors, customers, research findings and conclusion, appendix and data source.


Table of Contents

    1 Market Overview

    • 1.1 Peptide Cancer Vaccine Introduction
    • 1.2 Market Analysis by Type
      • 1.2.1 Type I
      • 1.2.2 Type II
    • 1.3 Market Analysis by Applications
      • 1.3.1 Breast Cancer
      • 1.3.2 Lung Cancer
      • 1.3.3 Melanoma
      • 1.3.4 Prostate Cancer
      • 1.3.5 Others
    • 1.4 Market Analysis by Regions
      • 1.4.1 North America (United States, Canada and Mexico)
        • 1.4.1.1 United States Market States and Outlook (2014-2024)
        • 1.4.1.2 Canada Market States and Outlook (2014-2024)
        • 1.4.1.3 Mexico Market States and Outlook (2014-2024)
      • 1.4.2 Europe (Germany, France, UK, Russia and Italy)
        • 1.4.2.1 Germany Market States and Outlook (2014-2024)
        • 1.4.2.2 France Market States and Outlook (2014-2024)
        • 1.4.2.3 UK Market States and Outlook (2014-2024)
        • 1.4.2.4 Russia Market States and Outlook (2014-2024)
        • 1.4.2.5 Italy Market States and Outlook (2014-2024)
      • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
        • 1.4.3.1 China Market States and Outlook (2014-2024)
        • 1.4.3.2 Japan Market States and Outlook (2014-2024)
        • 1.4.3.3 Korea Market States and Outlook (2014-2024)
        • 1.4.3.4 India Market States and Outlook (2014-2024)
        • 1.4.3.5 Southeast Asia Market States and Outlook (2014-2024)
      • 1.4.4 South America, Middle East and Africa
        • 1.4.4.1 Brazil Market States and Outlook (2014-2024)
        • 1.4.4.2 Egypt Market States and Outlook (2014-2024)
        • 1.4.4.3 Saudi Arabia Market States and Outlook (2014-2024)
        • 1.4.4.4 South Africa Market States and Outlook (2014-2024)
        • 1.4.4.5 Turkey Market States and Outlook (2014-2024)
    • 1.5 Market Dynamics
      • 1.5.1 Market Opportunities
      • 1.5.2 Market Risk
      • 1.5.3 Market Driving Force

    2 Manufacturers Profiles

    • 2.1 TapImmune
      • 2.1.1 Business Overview
      • 2.1.2 Peptide Cancer Vaccine Type and Applications
        • 2.1.2.1 Product A
        • 2.1.2.2 Product B
      • 2.1.3 TapImmune Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.2 BrightPath Biotherapeutics
      • 2.2.1 Business Overview
      • 2.2.2 Peptide Cancer Vaccine Type and Applications
        • 2.2.2.1 Product A
        • 2.2.2.2 Product B
      • 2.2.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.3 Ultimovacs
      • 2.3.1 Business Overview
      • 2.3.2 Peptide Cancer Vaccine Type and Applications
        • 2.3.2.1 Product A
        • 2.3.2.2 Product B
      • 2.3.3 Ultimovacs Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.4 Sellas
      • 2.4.1 Business Overview
      • 2.4.2 Peptide Cancer Vaccine Type and Applications
        • 2.4.2.1 Product A
        • 2.4.2.2 Product B
      • 2.4.3 Sellas Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.5 Boston Biomedical
      • 2.5.1 Business Overview
      • 2.5.2 Peptide Cancer Vaccine Type and Applications
        • 2.5.2.1 Product A
        • 2.5.2.2 Product B
      • 2.5.3 Boston Biomedical Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.6 Imugene
      • 2.6.1 Business Overview
      • 2.6.2 Peptide Cancer Vaccine Type and Applications
        • 2.6.2.1 Product A
        • 2.6.2.2 Product B
      • 2.6.3 Imugene Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.7 VAXON Biotech
      • 2.7.1 Business Overview
      • 2.7.2 Peptide Cancer Vaccine Type and Applications
        • 2.7.2.1 Product A
        • 2.7.2.2 Product B
      • 2.7.3 VAXON Biotech Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.8 Generex Biotechnology
      • 2.8.1 Business Overview
      • 2.8.2 Peptide Cancer Vaccine Type and Applications
        • 2.8.2.1 Product A
        • 2.8.2.2 Product B
      • 2.8.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.9 ISA Pharmaceuticals
      • 2.9.1 Business Overview
      • 2.9.2 Peptide Cancer Vaccine Type and Applications
        • 2.9.2.1 Product A
        • 2.9.2.2 Product B
      • 2.9.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.10 OncoTherapy Science
      • 2.10.1 Business Overview
      • 2.10.2 Peptide Cancer Vaccine Type and Applications
        • 2.10.2.1 Product A
        • 2.10.2.2 Product B
      • 2.10.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.11 Immatics
      • 2.11.1 Business Overview
      • 2.11.2 Peptide Cancer Vaccine Type and Applications
        • 2.11.2.1 Product A
        • 2.11.2.2 Product B
      • 2.11.3 Immatics Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)

    3 Global Peptide Cancer Vaccine Sales, Revenue, Market Share and Competition by Manufacturer (2017-2018)

    • 3.1 Global Peptide Cancer Vaccine Sales and Market Share by Manufacturer (2017-2018)
    • 3.2 Global Peptide Cancer Vaccine Revenue and Market Share by Manufacturer (2017-2018)
    • 3.3 Market Concentration Rate
      • 3.3.1 Top 3 Peptide Cancer Vaccine Manufacturer Market Share in 2018
      • 3.3.2 Top 6 Peptide Cancer Vaccine Manufacturer Market Share in 2018
    • 3.4 Market Competition Trend

    4 Global Peptide Cancer Vaccine Market Analysis by Regions

    • 4.1 Global Peptide Cancer Vaccine Sales, Revenue and Market Share by Regions
      • 4.1.1 Global Peptide Cancer Vaccine Sales and Market Share by Regions (2014-2019)
      • 4.1.2 Global Peptide Cancer Vaccine Revenue and Market Share by Regions (2014-2019)
    • 4.2 North America Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
    • 4.3 Europe Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
    • 4.4 Asia-Pacific Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
    • 4.5 South America Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
    • 4.6 Middle East and Africa Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)

    5 North America Peptide Cancer Vaccine by Country

    • 5.1 North America Peptide Cancer Vaccine Sales, Revenue and Market Share by Country
      • 5.1.1 North America Peptide Cancer Vaccine Sales and Market Share by Country (2014-2019)
      • 5.1.2 North America Peptide Cancer Vaccine Revenue and Market Share by Country (2014-2019)
    • 5.2 United States Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
    • 5.3 Canada Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
    • 5.4 Mexico Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)

    6 Europe Peptide Cancer Vaccine by Country

    • 6.1 Europe Peptide Cancer Vaccine Sales, Revenue and Market Share by Country
      • 6.1.1 Europe Peptide Cancer Vaccine Sales and Market Share by Country (2014-2019)
      • 6.1.2 Europe Peptide Cancer Vaccine Revenue and Market Share by Country (2014-2019)
    • 6.2 Germany Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
    • 6.3 UK Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
    • 6.4 France Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
    • 6.5 Russia Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
    • 6.6 Italy Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)

    7 Asia-Pacific Peptide Cancer Vaccine by Country

    • 7.1 Asia-Pacific Peptide Cancer Vaccine Sales, Revenue and Market Share by Country
      • 7.1.1 Asia-Pacific Peptide Cancer Vaccine Sales and Market Share by Country (2014-2019)
      • 7.1.2 Asia-Pacific Peptide Cancer Vaccine Revenue and Market Share by Country (2014-2019)
    • 7.2 China Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
    • 7.3 Japan Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
    • 7.4 Korea Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
    • 7.5 India Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
    • 7.6 Southeast Asia Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)

    8 South America Peptide Cancer Vaccine by Country

    • 8.1 South America Peptide Cancer Vaccine Sales, Revenue and Market Share by Country
      • 8.1.1 South America Peptide Cancer Vaccine Sales and Market Share by Country (2014-2019)
      • 8.1.2 South America Peptide Cancer Vaccine Revenue and Market Share by Country (2014-2019)
    • 8.2 Brazil Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
    • 8.3 Argentina Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
    • 8.4 Colombia Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)

    9 Middle East and Africa Peptide Cancer Vaccine by Countries

    • 9.1 Middle East and Africa Peptide Cancer Vaccine Sales, Revenue and Market Share by Country
      • 9.1.1 Middle East and Africa Peptide Cancer Vaccine Sales and Market Share by Country (2014-2019)
      • 9.1.2 Middle East and Africa Peptide Cancer Vaccine Revenue and Market Share by Country (2014-2019)
    • 9.2 Saudi Arabia Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
    • 9.3 Turkey Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
    • 9.4 Egypt Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
    • 9.5 Nigeria Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
    • 9.6 South Africa Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)

    10 Global Peptide Cancer Vaccine Market Segment by Type

    • 10.1 Global Peptide Cancer Vaccine Sales, Revenue and Market Share by Type (2014-2019)
      • 10.1.1 Global Peptide Cancer Vaccine Sales and Market Share by Type (2014-2019)
      • 10.1.2 Global Peptide Cancer Vaccine Revenue and Market Share by Type (2014-2019)
    • 10.2 Type I Sales Growth and Price
      • 10.2.1 Global Type I Sales Growth (2014-2019)
      • 10.2.2 Global Type I Price (2014-2019)
    • 10.3 Type II Sales Growth and Price
      • 10.3.1 Global Type II Sales Growth (2014-2019)
      • 10.3.2 Global Type II Price (2014-2019)

    11 Global Peptide Cancer Vaccine Market Segment by Application

    • 11.1 Global Peptide Cancer Vaccine Sales Market Share by Application (2014-2019)
    • 11.2 Breast Cancer Sales Growth (2014-2019)
    • 11.3 Lung Cancer Sales Growth (2014-2019)
    • 11.4 Melanoma Sales Growth (2014-2019)
    • 11.5 Prostate Cancer Sales Growth (2014-2019)
    • 11.6 Others Sales Growth (2014-2019)

    12 Peptide Cancer Vaccine Market Forecast (2019-2024)

    • 12.1 Global Peptide Cancer Vaccine Sales, Revenue and Growth Rate (2019-2024)
    • 12.2 Peptide Cancer Vaccine Market Forecast by Regions (2019-2024)
      • 12.2.1 North America Peptide Cancer Vaccine Market Forecast (2019-2024)
      • 12.2.2 Europe Peptide Cancer Vaccine Market Forecast (2019-2024)
      • 12.2.3 Asia-Pacific Peptide Cancer Vaccine Market Forecast (2019-2024)
      • 12.2.4 South America Peptide Cancer Vaccine Market Forecast (2019-2024)
      • 12.2.5 Middle East and Africa Peptide Cancer Vaccine Market Forecast (2019-2024)
    • 12.3 Peptide Cancer Vaccine Market Forecast by Type (2019-2024)
      • 12.3.1 Global Peptide Cancer Vaccine Sales Forecast by Type (2019-2024)
      • 12.3.2 Global Peptide Cancer Vaccine Market Share Forecast by Type (2019-2024)
    • 12.4 Peptide Cancer Vaccine Market Forecast by Application (2019-2024)
      • 12.4.1 Global Peptide Cancer Vaccine Sales Forecast by Application (2019-2024)
      • 12.4.2 Global Peptide Cancer Vaccine Market Share Forecast by Application (2019-2024)

    13 Sales Channel, Distributors, Traders and Dealers

    • 13.1 Sales Channel
      • 13.1.1 Direct Marketing
      • 13.1.2 Indirect Marketing
      • 13.1.3 Marketing Channel Future Trend
    • 13.2 Distributors, Traders and Dealers

    14 Research Findings and Conclusion

      15 Appendix

      • 15.1 Methodology

      Summary:
      Get latest Market Research Reports on Peptide Cancer Vaccine . Industry analysis & Market Report on Peptide Cancer Vaccine is a syndicated market report, published as Global Peptide Cancer Vaccine Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024. It is complete Research Study and Industry Analysis of Peptide Cancer Vaccine market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      		$3,480.00
      		$5,220.00
      		$6,960.00
      		2,784.00
      		4,176.00
      		5,568.00
      		3,250.32
      		4,875.48
      		6,500.64
      		547,508.40
      		821,262.60
      		1,095,016.80
      		290,197.20
      		435,295.80
      		580,394.40
      Credit card Logo
      Sample Question Discount Download PDF

      Related Reports

      Reason to Buy

      • Trusted By Leaders

        Top executives from leading companies purchase research reports from us. 

      • Shop With Confidence

        We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

      • Customer Centric

        Need assistance related to your research requirements? We are just a phone call or an email away.

      • Personalized Solutions

        Our experienced research specialists are here to help you locate the right reports for your need.

      • Secure Checkout

        Shop without being worried about safety & security of your transactions.
        •

      Request for Sample of this report

      Reports and Markets

      mcafree

      Contact Us

      +1-352-353-0818 (US)

      info@reportsandmarkets.com

      Support

      EMAIL US

      Newsletter

      KEEP UP TO DATE ON ALL THE LATEST REPORTS


      maxmind_logo